PL368458A1 - Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka - Google Patents

Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka

Info

Publication number
PL368458A1
PL368458A1 PL02368458A PL36845802A PL368458A1 PL 368458 A1 PL368458 A1 PL 368458A1 PL 02368458 A PL02368458 A PL 02368458A PL 36845802 A PL36845802 A PL 36845802A PL 368458 A1 PL368458 A1 PL 368458A1
Authority
PL
Poland
Prior art keywords
cancer therapy
improved use
antitumoral compound
antitumoral
compound
Prior art date
Application number
PL02368458A
Other languages
English (en)
Inventor
Jose Jimeno
Casado Ana Ruiz
Lazaro Luis Lopez
Eric Rowinsky
Manuel Hidalgo
Original Assignee
Pharmamar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar S.A. filed Critical Pharmamar S.A.
Publication of PL368458A1 publication Critical patent/PL368458A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
  • Medicinal Preparation (AREA)
PL02368458A 2001-10-19 2002-10-21 Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka PL368458A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34841401P 2001-10-19 2001-10-19

Publications (1)

Publication Number Publication Date
PL368458A1 true PL368458A1 (pl) 2005-03-21

Family

ID=23367939

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368458A PL368458A1 (pl) 2001-10-19 2002-10-21 Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka

Country Status (15)

Country Link
US (1) US20050004018A1 (pl)
EP (1) EP1435988A4 (pl)
JP (1) JP2005509650A (pl)
KR (1) KR20050038578A (pl)
CN (1) CN1606449A (pl)
AU (1) AU2002343548B2 (pl)
BR (1) BR0213424A (pl)
CA (1) CA2462502A1 (pl)
HU (1) HUP0401903A3 (pl)
IL (1) IL161430A0 (pl)
MX (1) MXPA04003674A (pl)
NO (1) NO20042035L (pl)
PL (1) PL368458A1 (pl)
RU (1) RU2306933C2 (pl)
WO (1) WO2003039571A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
NZ552607A (en) * 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
ES2433424T3 (es) * 2008-08-15 2013-12-11 Merrimack Pharmaceuticals, Inc. Métodos y sistemas para predecir respuesta de células frente a un agente terapéutico
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
EP2919772B1 (en) 2012-11-13 2019-03-27 NuSirt Sciences, Inc. Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
SI4101855T1 (sl) 2017-04-27 2024-03-29 Pharma Mar S.A. Protitumorske spojine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
AU780417B2 (en) * 1999-11-15 2005-03-17 Pharma Mar S.A. Aplidine treatment of cancers
CZ304749B6 (cs) * 2000-04-12 2014-09-24 Pharma Mar, S. A. Ecteinascidin mající pět spojených kruhů s 1,4-můstkem, farmaceutický prostředek, použití a způsob
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide

Also Published As

Publication number Publication date
KR20050038578A (ko) 2005-04-27
AU2002343548B2 (en) 2007-11-08
JP2005509650A (ja) 2005-04-14
CA2462502A1 (en) 2003-05-15
EP1435988A4 (en) 2008-01-09
AU2002343548B8 (en) 2003-05-19
NO20042035L (no) 2004-05-18
CN1606449A (zh) 2005-04-13
IL161430A0 (en) 2004-09-27
RU2004115110A (ru) 2005-03-10
BR0213424A (pt) 2004-12-14
WO2003039571A1 (en) 2003-05-15
EP1435988A1 (en) 2004-07-14
HUP0401903A3 (en) 2008-07-28
MXPA04003674A (es) 2004-07-23
HUP0401903A2 (hu) 2005-01-28
RU2306933C2 (ru) 2007-09-27
US20050004018A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
EP1435988A4 (en) IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
IL251270A0 (en) Cancer treatment
PL370029A1 (pl) Pochodne 2-amino-4-heteroaryloaminopirymidyny do stosowania w leczeniu raka
EP1463438A4 (en) ENDOMURAL THERAPY
IL164599A0 (en) Combination therapy for the treatment of cancer
IL159887A0 (en) Combination therapy for the treatment of cancer
EP1463495A4 (en) AGENTS AND METHODS FOR TREATING CANCER
PL368035A1 (pl) Kompozycje i sposoby leczenia raka
GB0101933D0 (en) Therapy
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
AU9402401A (en) Treatment of cancers
EP1463511A4 (en) COMBINATORY ANTICANCER THERAPY
GB0222409D0 (en) Use of antitumoral compounds in cancer therapy
SI1427420T1 (sl) Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka
GB0128122D0 (en) Therapeutic use
GB0118627D0 (en) Use of compounds in therapy
GB0129451D0 (en) Treatment of cancer
GB0008161D0 (en) Treatment of cancer
GB0115870D0 (en) Tumour therapy
GB0015215D0 (en) Tumour therapy
GB0017625D0 (en) Use of compounds in therapy
GB0030058D0 (en) Use of compounds in therapy
GB0012945D0 (en) Use of compounds in therapy
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
GB0115943D0 (en) Treatment and diagosis of cancer

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)